EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The spectrum of amyloid cardiovascular disease

Filippos Triposkiadis, Randall C Starling, Mazen Hanna, Andrew Xanthopoulos

Heart Failure Reviews · 09.11.2026 · 31 (1)

DOI: 10.1007/s10741-026-10693-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 09.11.2026. Verfasst von Filippos Triposkiadis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Thessaly, Larissa, Greece. ftriposkiadis@gmail.com. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies, Heart Failure, Myocardium. Die Arbeit nennt 140 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac amyloidosis, historically characterized as a restrictive cardiomyopathy, is now understood as a multi-compartmental disorder. Atrial amyloid infiltration-whether ANP-derived isolated atrial amyloidosis secondary to atrial stretch, or primary atrial ATTR infiltration-produces an atrial cardiomyopathy that frequently manifests as atrial fibrillation and a thrombogenic substrate even in sinus rhythm. Cardiac amyloidosis exhibits a high prevalence in heart failure, particularly among elderly patients presenting with preserved ejection fraction. Furthermore, TTR amyloid frequently coexists with degenerative aortic stenosis, and amyloid deposits are also found in the coronary microcirculation and the aorta. Given the current availability of efficacious treatments for amyloidosis, the recognition of these diverse clinical manifestations is paramount for achieving accurate diagnosis, appropriate risk stratification, and timely therapeutic intervention to enhance cardiovascular outcomes. This review frames amyloid cardiovascular disease as a multisystem process affecting the myocardium, atria, valves, and vasculature-often with extracardiac red flags-rather than solely as an infiltrative ventricular cardiomyopathy. Actionable implications currently concentrate on ventricular ATTR/AL cardiomyopathy and concomitant aortic stenosis; coronary and aortic medial deposits remain mechanistically important research targets rather than independently treatable lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisCardiomyopathiesHeart FailureMyocardiumHumansHeart Atria

Stichwörter der Autor:innen

Aortic stenosisAtrial fibrillationCardiac amyloidosisHeart failureIsolated atrial amyloidosisTransthyretin

Autor:innen und Institutionen

  • Faculty of Medicine, University of Thessaly, Larissa, Greece. ftriposkiadis@gmail.com.
  • School of Medicine, European University Cyprus, Nicosia, Cyprus. ftriposkiadis@gmail.com.
  • , 39 Kirinias St., Papagos, 15669, Athens, Greece. ftriposkiadis@gmail.com.
  • Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Faculty of Medicine, University of Thessaly, Larissa, Greece.
  • School of Medicine, European University Cyprus, Nicosia, Cyprus.

Zitieren

APA

Triposkiadis, F., Starling, R. C., Hanna, M., & Xanthopoulos, A. (2026). The spectrum of amyloid cardiovascular disease. Heart Failure Reviews, 31(1). https://doi.org/10.1007/s10741-026-10693-5

Vancouver

Triposkiadis F, Starling RC, Hanna M, Xanthopoulos A. The spectrum of amyloid cardiovascular disease. Heart Failure Reviews. 2026;31(1). doi:10.1007/s10741-026-10693-5

BibTeX
@article{Triposkiadis2026,
  author = {Triposkiadis, Filippos and Starling, Randall C and Hanna, Mazen and Xanthopoulos, Andrew},
  title = {The spectrum of amyloid cardiovascular disease},
  journal = {Heart Failure Reviews},
  year = {2026},
  volume = {31},
  number = {1},
  doi = {10.1007/s10741-026-10693-5}
}
Kostenlos starten →